Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Impaired Hepatic Function Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function

NCT07519135
View directory record Official record
Conditions
Healthy
Interventions
PF-08653944
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
Zongertinib (BI 1810631)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

NCT05481411
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Rialto, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

NCT01392807
View directory record Official record
Conditions
Hepatic; Functional Disturbance
Interventions
NKTR-118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

NCT06190691
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Edgewater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

NCT01762462
View directory record Official record
Conditions
Hepatic Impairment
Interventions
SAR302503
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 15, 2026, 2:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

NCT07343960
View directory record Official record
Conditions
Moderate Hepatic Impairment
Interventions
Capivasertib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Rialto, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

NCT02452801
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Evaluating Patients With Impaired Hepatic Function

NCT00398424
View directory record Official record
Conditions
Impaired Hepatic Function
Interventions
S-1/Cisplatin
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

NCT02808312
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Interventions
Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

NCT01299454
View directory record Official record
Conditions
Schizophrenia
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Miami, Florida • Minneapolis, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

NCT03562117
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

NCT05884554
View directory record Official record
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Anaheim, California • Garden Grove, California • Montclair, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

NCT05610657
View directory record Official record
Conditions
Moderate Hepatic Impairment
Interventions
Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Tustin, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 15, 2026, 2:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

NCT04136444
View directory record Official record
Conditions
Healthy Study Participants, Impaired Hepatic Function
Interventions
Padsevonil
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

NCT02161770
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 15, 2026, 2:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

NCT06997276
View directory record Official record
Conditions
Healthy, Hepatic Impairment
Interventions
Mirdametinib (MEK Inhibitor)
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

NCT06340347
View directory record Official record
Conditions
Liver Diseases
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Lake Forest, California • Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

NCT02524717
View directory record Official record
Conditions
Hepatic Impairment
Interventions
JNJ-56021927
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 15, 2026, 2:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

NCT07248839
View directory record Official record
Conditions
Healthy Volunteers, Hepatic Impairment
Interventions
BMS-986435
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320
View directory record Official record
Conditions
Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

NCT07401862
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
LY3841136
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

NCT00851227
View directory record Official record
Conditions
Liver Disease, Hyponatremia
Interventions
conivaptan hydrochloride
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
30 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 15, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

NCT03423446
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Telotristat Ethyl
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 15, 2026, 2:37 PM EDT